

IPOs

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
Deciphera (DCPH)	28-Sep-17	Waltham, MA	Developer of kinase-inhibiting drugs, including tumor-targeted therapies and immuno-targeted therapies, designed to treat cancer and immunological diseases.	127.50	JPM Securities

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Arquer Diagnostics	1-Sep-17	Sunderland, United Kingdom	Later Stage VC	Developer of proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples.	2.76	Undisclosed Investors
Forge Life Science	1-Sep-17	Doylestown, PA	Early Stage VC	Developer of small molecule antiviral therapeutics that target non-viral human proteins, known as sirtuins, and enhance their natural ability to fight powerful infections.	3.37	Mid Atlantic Bio Angels, Keiretsu Forum, Undisclosed Investors
General Biotechnologies	1-Sep-17	Cambridge, MA	Accelerator/ Incubator	Provider of services designed to bridge the gap between discoveries in the life sciences and meaningful real-world applications. The company's program de-risks transfers of tech assets from top research institutes, enabling them to build a portfolio of high-ROI biotech investments. The company's flagship program - Nivien Therapeutics - is a venture-backed oncology startup developing a novel platform to enhance IO-chemo combo therapies for treatment-resistant cancers.	0.25	IndieBio
Oncurious	1-Sep-17	Leuven, Belgium	Early Stage VC	Provider of biotechnology research services focused on clinical development activities in orphan pediatric oncology treatment with a focus on preclinical research and drug development programs.	2.48	VIB, ThromboGenics
ImpriMed	4-Sep-17	Palo Alto, CA	Accelerator/ Incubator	Provider of a high-throughput drug-sensitivity assay kit for precision medicine to pre-test a number of drug combinations on a cancer patient's biopsy samples and allow doctors to treat patients with personalized drug combinations.	Undisclosed	Pear Ventures
Accutis	5-Sep-17	Cumming, GA	Angel	Developer and marketer of pharmaceuticals for dermatological diseases.	1.75	Bio/Med Investor Network, Georgia Research Alliance, Robert Thomas, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Amal Therapeutics	5-Sep-17	Geneva, Switzerland	Early Stage VC	Developer of novel, peptide-based therapeutic cancer vaccines.	9.12	Boehringer Ingelheim Venture Fund, BioMedPartners, Helsinn Investment Fund, Schroder Adveq, High-Tech Gründerfonds, VI Partners
Entasis Therapeutics	5-Sep-17	Waltham, MA	Early Stage VC	Developer of antibacterial therapeutics targeting gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections and infections following surgery.	31.90	Pivotal bioVenture Partners, Sofinnova Ventures, TPG Biotech
Immunic Therapeutics	5-Sep-17	Planegg-Martinsried, Germany	Early Stage VC	Provider and developer of small molecule immune modulators that block T-helper type 1- and type 17-mediated immune and autoimmune responses to treat conditions including inflammatory bowel disease and psoriasis.	37.44	LifeCare Partners, Life Sciences Partners, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Bayern Kapital, High-Tech Gründerfonds, Bmp Beteiligungsmanagement, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Rational Vaccines	5-Sep-17	Springfield, IL	Seed Round	Developer of herpes simplex virus vaccines and serology tests.	8.20	Theil Capital, Founders Fund, IronBridge Capital, Abstract Capital, Undisclosed Investors
Skyland Analytics	5-Sep-17	Boulder, CO	Early Stage VC	Provider of manufacturing informatics software and process optimization, manufacturing IP, and compliance services to drug manufacturers and their contract manufacturing organizations.	0.89	Undisclosed Investors
Virometix	5-Sep-17	Schlieren, Switzerland	Angel	Developer of vaccines and immunotherapeutic drugs integrating rational molecular design, chemical synthesis, and a proprietary synthetic particle technology to prevent and treat infections and chronic human diseases.	1.24	Undisclosed Investors
Akonni Biosystems	6-Sep-17	Frederick, MD	Later Stage VC	Developer and manufacturer of a unique in-vitro diagnostic system based on proprietary gel-drop micro-array technology for rapid, reliable, multiplexed analysis in a low-cost format.	4.00	Undisclosed Investors
Cardiac Insight	6-Sep-17	Kirkland, WA	Later Stage VC	Developer of CardeaScreen, a body-worn sensing and computing monitor for applications in cardiology, respiratory assessments, and other complex disease states.	4.50	Undisclosed Investors
Excision	6-Sep-17	New York, NY	Seed Round	Developer of advanced gene editing therapeutics created to offer safe and efficacious medicines that will eradicate or disrupt viral genes in human patients.	10.00	ARTIS Ventures, Undisclosed Investors
OncoStem Diagnostics	6-Sep-17	Bangalore, India	Early Stage VC	Developer of a multimarker prognostic and predictive test that identifies risk of recurrence in patients with hormone receptor positive breast cancer from stage 1 through stage 3A.	6.00	Sequoia Capital India, Artiman Ventures
Peptomyc	6-Sep-17	Barcelona, Spain	Early Stage VC	Developer of peptide therapeutics targeting the Myc oncogene, a central function in cancer cell survival, designed to treat cancer.	4.96	Alta Life Sciences, HealthEquity, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Aprecia Pharmaceuticals	7-Sep-17	Langhorne, PA	Secondary Transaction - Private	Developer of a three-dimensional printed pharmaceutical platform designed to offer pharmaceuticals used to treat epilepsy and other central nervous system disorders.	Undisclosed	Undisclosed Investors
electroCore	7-Sep-17	Bernards, NJ	Later Stage VC	Developer of non-invasive vagus nerve stimulation therapies designed to treat multiple conditions in neurology, psychiatry, gastroenterology, and other fields.	36.00	Undisclosed Investors
Gritstone Oncology	7-Sep-17	Emeryville, CA	Early Stage VC	Operator of an immuno-oncology platform designed to develop next-generation personalized cancer therapeutics.	92.70	Lilly Asia Ventures, GV, Trinitas Capital (Beijing), Alexandria Venture Investments, Versant Venture Management, The Column Group, Clarus Ventures, Frazier Healthcare Partners
Sync Think	7-Sep-17	Boston, MA	Early Stage VC	Developer of eye-tracking metrics and devices designed to give medical professionals objective metrics for visual attention.	1.92	Undisclosed Investors
WuXi NextCODE	7-Sep-17	Cambridge, MA	Early Stage VC	Provider of a global genomics platform created to provide genomic sequence data.	240.00	Sequoia Capital China, Temasek Holdings, Amgen Ventures, Ally Bridge Group, Yunfeng Capital, 3W Partners

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Replimune	8-Sep-17	Woburn, MA	Early Stage VC	Provider of a therapeutic treatment designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes.	55.00	Foresite Capital, Bain Capital, Redmile Group, Cormorant Asset Management, Atlas Venture, Forbion Capital Partners, Omega Funds
Rani Therapeutics	9-Sep-17	San Jose, CA	Later Stage VC	Developer of a novel approach for the delivery of large drug molecules, including peptides, proteins, and antibodies, by converting injectable drugs into oral pills.	39.00	GV, Novartis, AstraZeneca, Cathay Ventures, Joseph Gunnar and Co, through their Buttonwood Alpha Fund, Crystal Horizon Investments, Pinemount Investments, Pacific Venture Opportunity Fund, Bossa Nova Investimentos
Expanesthetics	11-Sep-17	Davis, CA	Angel	Developer of general anesthetic products and pain drugs to help hospitals and surgery centers manage surgical pain.	1.68	Undisclosed Investors
SpecificiT Pharma	11-Sep-17	Montreal, Canada	Seed Round	Developer of cellular therapies created to revolutionize the treatment of hematological cancers.	Undisclosed	GeneChem Management, Sanderling Ventures, Accel-Rx

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Arch BioPartners (ARCH)	12-Sep-17	Toronto, Canada	PIPE	Developer of diagnosis and treatment methods for acute and chronic diseases.	0.20	Undisclosed Investors
DNA Script	12-Sep-17	Paris, France	Early Stage VC	Developer of a DNA synthesis technology that overcomes the current inefficiencies of synthetic DNA production and enables affordable, rapid, high-quality, and high-throughput production of synthetic biology tools, such as oligonucleotides, genes, pathways, and genomes.	12.99	Illumina Ventures, Sofinnova Partners, Merck Ventures, Kurma Partners, Idinvest Partners
Green Dot Labs	12-Sep-17	Boulder, CO	Early Stage VC	Producer of marijuana for licensed medical marijuana centers.	3.30	Tuatara Capital
H3D	12-Sep-17	Ann Arbor, MI	Angel	Developer of gamma-ray imaging spectrometers for use in various applications, including proton cancer therapy.	2.80	Undisclosed Investors
Kineta	12-Sep-17	Seattle, WA	Later Stage VC	Developer of translational and immune modulating drugs to cure autoimmune diseases, viral diseases, and severe pain.	5.50	Undisclosed Investors
Paragon Genomics	12-Sep-17	Hayward, CA	Early Stage VC	Provider of rapid, easy-to-use, and ultra-high multiplex PCR-based target enrichment services for the next-generation sequencing markets.	8.00	Shenzhen Cowin Venture Capital Investments, Fosun Industrial Holdings, Cloudstone Venture, Heda Ventures, Wisemont Capital

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
BridgeBio	13-Sep-17	Palo Alto, CA	PE Growth/ Expansion	Developer of genetically targeted therapies intended to treat rare diseases.	135.00	Aisling Capital, American International Group, Cormorant Capital, Kohlberg Kravis Roberts, Perceptive Advisors, Viking Global Investors, Janus Capital Group
Genenta Science	13-Sep-17	Milan, Italy	Angel	Developer of a gene transfer strategy intended to provide autologous hematopoietic stem cells to target interferon- α expression to tumor-infiltrating macrophages.	8.27	Club degli Investitori, ProVation Medical, Ferragamo Finanziaria, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
GreenLight Biosciences	13-Sep-17	Medford, MA	Later Stage VC	Developer of a cell-free bio-processing platform designed to ensure sustainable global development with bio-processed RNA.	18.00	Fall Line Capital, Seed 2 Growth Ventures, Lewis and Clark Ventures, Macro Capital Investments, Kodiak Venture Partners, Spruce Capital Partners, Syngenta Ventures, Undisclosed Investors
Oncora Medical	13-Sep-17	Philadelphia, PA	Seed Round	Developer of a software platform that uses predictive analytics to unify data on radiation oncology.	1.89	Ben Franklin Technology Partners, Undisclosed Investors
Sophia Genetics	13-Sep-17	Saint Sulpice, Switzerland	Later Stage VC	Developer of a clinical genomics analysis platform.	30.00	Balderton Capital, 360 Capital Partners, Invoke Capital, Alychlo
TwinStrand Biosciences	13-Sep-17	Seattle, WA	Seed Round	Developer of a next generation DNA sequencing therapy created to detect ultra-rare variants that are invisible by other sequencing approaches.	5.28	Undisclosed Investors
Grid Therapeutics	14-Sep-17	Durham, NC	Early Stage VC	Developer of a targeted immunotherapy created to not only directly kill tumor cells without detrimental effects on normal tissues, but also modulate the adaptive immune response to attack tumor cells anywhere in the body.	Undisclosed	Longview International, Duke University

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
ImaginAb	14-Sep-17	Inglewood, CA	Later Stage VC	Developer of engineered antibody fragments for diagnostic imaging and radio immunotherapy intended to leverage the exquisite specificity of monoclonal antibodies to create precise images of disease activity.	7.67	Undisclosed Investors
Micell Technologies	14-Sep-17	Durham, NC	Later Stage VC	Developer of drug-delivery systems for cardiovascular diseases.	61.78	Undisclosed Investors
Synspira	14-Sep-17	Boston, MA	Angel	Developer of glycopolymer-based therapeutics to treat and alter the progression of pulmonary diseases by disrupting mucus accumulation and bacterial bio-film invasion.	8.24	Undisclosed Investors
Apotheca Biosciences	15-Sep-17	Saint Petersburg, FL	Secondary Transaction - Private	Developer of transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.	Undisclosed	FutureLand
GTN (Generative Tensorial Networks)	15-Sep-17	London, United Kingdom	Accelerator/ Incubator	Provider of a drug discovery platform that combines quantum physics and machine learning algorithms to transform search and discovery of patient-centered drugs.	0.10	Entrepreneur First
Orbis Health Solutions	15-Sep-17	Greenville, SC	Angel	Developer of improved methods to stimulate a patient's immune system and enhance its ability to recognize and destroy disease entities.	2.80	Undisclosed Investors
Provista Diagnostics	15-Sep-17	New York, NY	Later Stage VC	Provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries.	16.04	Undisclosed Investors
Aspect Biosystems	18-Sep-17	Vancouver, Canada	Early Stage VC	Provider of a 3D bioprinting technology capable of creating human tissues on demand, primarily for human tissue models in pre-clinical drug discovery.	Undisclosed	Pangaea Ventures, Endure Capital, Pallasite Ventures, Relentless Pursuit Partners, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Cofactor Genomics	18-Sep-17	Saint Louis, MO	Later Stage VC	Operator of a biotechnology company that provides full genome sequencing, sequence assembly, expressed sequence tagging, gene alignments, and sequence analysis to enable detection and diagnosis of diseases and translate next-generation sequencing-based technologies into stable and complete end-to-end product solutions through R&D developments that combine molecular, sequencing, and bioinformatics.	18.00	Menlo Ventures, AME Cloud Ventures, BioGenerator, Ascension Ventures, iSelect Fund, Wilson Sonsini Goodrich & Rosati, Stanford, Data Collective, 7percent ventures, Refactor Capital, SV Tech Ventures, David Lee, Jude Gomila, Paul Bucheit, Y Combinator
Immunocore	18-Sep-17	Abingdon, United Kingdom	Later Stage VC	Developer of immunotherapeutic drugs intended to exploit and enhance the body's own immune system.	40.00	Bill & Melinda Gates Foundation
Kaleido BioSciences	18-Sep-17	Bedford, MA	Early Stage VC	Developer of a R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health.	37.10	Flagship Pioneering, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
LifeMine Therapeutics	18-Sep-17	Cambridge, MA	Early Stage VC	Developer of novel drugs by exploiting small molecule evolution in fungi to discover game-changing therapeutics.	55.00	WuXi Healthcare Ventures, Foresite Capital, GV, Arch Venture Partners, Boyu Capital, Blue Pool Capital, Merck Ventures, Alexandria Venture Investments
Rodin Therapeutics	18-Sep-17	Cambridge, MA	Early Stage VC	Developer of epigenetic drugs for the treatment of cognitive disorders and diseases of the brain.	27.00	Hatteras Venture Partners, Atlas Venture, GV, Reditex Ventures, Third Point Ventures
Disarm	19-Sep-17	Cambridge, MA	Early Stage VC	Developer of therapeutics created to treat patients with neurological diseases by preventing axonal degeneration.	30.00	Atlas Venture, BioGenerator, Lightstone Ventures, AbbVie Ventures
Enlivex Therapeutics	19-Sep-17	Jerusalem, Israel	Later Stage VC	Developer of an autologous and allogeneic drug pipeline designed for the treatment of autoimmune and inflammatory conditions that involve over-expression or hyper-expression of cytokines.	8.00	Korea Investment Partners, Hadasit Bio Holding
Procaps	19-Sep-17	Barranquilla, Colombia	PE Growth/Expansion	Manufacturer of medicines with activities ranging from product development to pharmaceutical production and distribution.	Undisclosed	International Finance Corporation

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Synthace	19-Sep-17	London, United Kingdom	Later Stage VC	Developer of a language and software platform designed to bring end-to-end digitization to biotechnology.	9.47	White Cloud Capital, Amadeus Capital Partners, Sofinnova Partners, SOSV, Bioeconomy Capital
Tolremo Therapeutics	19-Sep-17	Zurich, Switzerland	Seed Round	Developer of novel targeted therapeutics for the treatment of cancer.	2.49	Undisclosed Investors
Biomark Diagnostics (BUX)	20-Sep-17	Richmond, Canada	PIPE	Developer of advanced stage diagnostic technologies intended to increase the accuracy of cancer diagnostics.	0.66	Undisclosed Investors
Critical Outcome Technologies (COT)	20-Sep-17	London, Canada	PIPE	Developer of targeted therapeutic products for ovarian and other gynecological cancers that help restore normal cell signaling in cancer with p53 mutations.	1.50	Undisclosed Investors
Edesa Biotech	20-Sep-17	Markham, Canada	Early Stage VC	Operator of a clinical-stage firm intended to develop dermatological and anorectal drugs.	7.00	Lumira Capital, Pharmascience, Cipher Pharmaceuticals, Inveready Technology Investment Group, Yissum, Undisclosed Investors
M2gen	20-Sep-17	Tampa, FL	Later Stage VC	Developer of a health informatics-based tool intended to accelerate the discovery, development, and delivery of personalized medicine for cancer therapies.	75.00	Hearst Health

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
XW Laboratories	20-Sep-17	Wuhan, China	Early Stage VC	Developer of a bio-pharmaceutical platform designed to improve the pharmacokinetics and safety profiles of existing drugs and find potential new indications, enabling doctors to reduce damage to the mitochondria and treat neurological disorders.	17.50	Elements Capital and WI Harper Group, KTB Network, Kleiner Perkins Caufield & Byers, Johnson & Johnson Innovation - JJDC, WuXi Healthcare Investment Consulting (Shanghai)
Precision Health Intelligence	21-Sep-17	New York, NY	Corporate	Developer of an artificial intelligence platform focused on oncology.	20.00	Symphony AI
Tilos Therapeutics	21-Sep-17	Cambridge, MA	Seed Round	Developer of antibody therapeutics designed to treat cancer, fibrosis, and related disorders.	3.05	Undisclosed Investors
TripleMed	21-Sep-17	Maastricht, Netherlands	Later Stage VC	Provider of biotechnology research and development services focused on the treatment of aortic aneurysms.	2.36	Chemelot Ventures, Limburg Business Development Fund, Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Bellen	22-Sep-17	Beijing, China	Later Stage VC	Operator of a medical contract research organization developing chemical synthesis for innovative chemical drugs.	37.44	Legend Capital, China International Capital Corporation, Gefeiyouren, Dachen Chuanglian, Dianjing Shijie
DelMar Pharmaceuticals (DMPI)	22-Sep-17	Vancouver, Canada	PIPE	Developer of therapies used for the treatment of brain cancer, cell lung cancer, and ovarian cancer.	10.00	Undisclosed Investors
Promaxo	22-Sep-17	Rockville, MD	Early Stage VC	Developer of an office-based, portable MRI with cellular spatial resolution and real-time targeted biopsy and treatment tools created to transform prostate cancer disease management.	3.79	MicroPort Scientific, Keiretsu Forum, Undisclosed Investors
Tempus Health	22-Sep-17	Chicago, IL	Later Stage VC	Developer of a healthcare data analytics platform designed to enable personalized cancer care.	70.00	New Enterprise Associates, Revolution Group
ADC Biotechnology	25-Sep-17	Saint Asaph, United Kingdom	PE Growth/Expansion	Developer of new antibody drug conjugates and anti-cancer therapies that target specific cancer cells where they are internalized prior to release of the drugs.	Undisclosed	Maven Capital Partners, Finance Wales, Seneca Partners UK
Alcresta Therapeutics	25-Sep-17	Newton, MA	Later Stage VC	Developer of enzyme-based nutritional products that help in breaking down complex foods to manage disease for infants, older adults, and patients battling acute or chronic conditions.	60.89	Athyrium Capital Management, Bessemer Venture Partners, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
BrainSpec	25-Sep-17	Boston, MA	Early Stage VC	Operator of a health technology company created to diagnose brain disorders using an efficient and radiation-free approach that involves software and magnetic resonance spectroscopy.	1.73	Data Collective, Undisclosed Investors
Deep Genomics	25-Sep-17	Toronto, Canada	Early Stage VC	Developer of an integrated genetic computational system that alters crucial cellular processes, including transcription, splicing, polyadenylation, and translation, leading to effective therapies.	13.00	Khosla Ventures, True Ventures
Fusion Pharmaceuticals	25-Sep-17	Hamilton, Canada	Early Stage VC	Developer of novel targeted alpha therapeutics for chemotherapy resistant cancers created to leverage radioactivity in relatively low doses to attack cancer cells.	46.00	Johnson & Johnson Innovation - JJDC, Fight Against Cancer Innovation Trust, Genesys Capital, HealthCap, Adams Street Partners, Seroba Life Sciences, Varian Medical Systems, TPG Biotech
SpringWorks Therapeutics	25-Sep-17	Baltimore, MD	Early Stage VC	Developer of therapeutic drugs for rare diseases, such as desmoid tumors, neurofibromatosis, hereditary xerocytosis, and post-traumatic stress disorder.	103.00	Bain Capital, OrbiMed, LifeArc, Pfizer
Autolus	26-Sep-17	London, United Kingdom	Later Stage VC	Developer of T-cell immunotherapy products intended for the treatment of cancer.	80.00	Syncona, Woodford Investment Management, Cormorant Asset Management, Nextech Invest, Arix Bioscience

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Eligo Bioscience	26-Sep-17	Paris, France	Early Stage VC	Developer of antibiotics intended for microbiome precision-editing and bacteria-associated diseases.	20.00	Khosla Ventures, Seventure Partners
Newron Pharmaceuticals (NWRN)	26-Sep-17	Milan, Italy	PIPE	Provider of pharmaceutical products intended to develop novel therapies for pain and for diseases of the central nervous system.	27.97	Undisclosed Investors
The Cronos Group (MJN)	26-Sep-17	Toronto, Canada	PIPE	Distributor of medical cannabis.	11.90	Undisclosed Investors
Venneos	26-Sep-17	Stuttgart, Germany	Early Stage VC	Developer of a silicon-chip-based imaging system designed to analyze biological cells.	Undisclosed	Born2Grow, High-Tech Gründerfonds, Venneos Beteiligungs, Max Planck Innovation
Analytics for Life	27-Sep-17	Kingston, Canada	Angel	Developer of a cardiac monitoring device using advanced signal processing techniques and machine-learned algorithms to reveal previously hidden information about a patient's health status from within their physiological signals in the coronary artery.	19.84	Undisclosed Investors
Engage Therapeutics	27-Sep-17	Summit, NJ	Early Stage VC	Developer of a new drug-device combination therapy for people who experience uncontrolled epileptic seizures.	23.00	TPG Biotech, Adage Capital Management, Lifescivc, Lumira Capital

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Excicure	27-Sep-17	Skokie, IL	Later Stage VC	Developer of immunomodulatory and gene silencing drugs for the treatment of inflammatory disorders.	20.00	Mark Tompkins and Katalyst Securities, AbbVie Ventures, William Gates, Eric Lefkofsky, Craig Mundie, Patrick G. Ryan, David Walt, Undisclosed Investors
LNC Therapeutics	27-Sep-17	Bordeaux, France	Later Stage VC	Developer of drugs created to target obesity and associated cardiometabolic diseases through an action on the gut microbiota and the intestinal membrane.	7.68	Seventure Partner, Undisclosed Investors
Oncimmune (ONC)	27-Sep-17	Nottingham, United Kingdom	PIPE	Developer of autoantibody assay technologies that stratify indeterminate pulmonary nodules for the risk of malignancy, enabling doctors to perform a blood test to assess risk and detect lung cancer in its early stages.	6.48	Undisclosed Investors
Advanced Proteome Therapeutics (APTCF)	28-Sep-17	Boston, MA	PIPE	Developer of anti-cancer therapeutics that exploit the properties of a natural human protein.	0.64	Undisclosed Investors
Lung Passport	28-Sep-17	Minsk, Belarus	Early Stage VC	Developer of an automated lung diagnostic system created to monitor the state of chronic disease and enable patients to control their lung condition and detect respiratory diseases early on.	0.10	Spacemind Capital
Magenta Medical	28-Sep-17	Ashkelon, Israel	Early Stage VC	Developer of a temporary venous catheter-based therapy created to treat acute decompensated heart failure.	15.00	Abiomed, Pitango Venture Capital, Jafco, Jacques Seguin
Midatech Pharma (MTPH)	28-Sep-17	Abingdon, United Kingdom	PIPE	Manufacturer of pharmaceuticals focused on oncology and other therapeutic areas.	10.37	Undisclosed Investors

Private Equity Placements and Venture Capital Rounds

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
VoxelCloud	28-Sep-17	Los Angeles, CA	Early Stage VC	Provider of artificial intelligence imaging technology that offers medical images, data analytics, and decision support through cutting-edge machine learning and validation from massive, real-world training data.	15.00	Tencent, Sequoia Capital, United Capital Investment
DeepWave	29-Sep-17	London, United Kingdom	Seed Round	Developer of a wearable technology platform that uses neuroscience to improve sleep as the gateway to enhanced cognitive functioning and health.	Undisclosed	Deep Knowledge Ventures
Geno	29-Sep-17	Cocoa, FL	PE Growth/Expansion	Developer of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases.	29.94	Undisclosed Investors
Peptilogics	29-Sep-17	Pittsburgh, PA	Early Stage VC	Developer of a technology platform for designing novel peptide antibiotics that inactivate drug-resistant bacteria for rapid selection.	5.50	Peter Thiel, Stefan Roever, BlueTree Allied Angels, Undisclosed Investors

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
CSL	Calimmune	Tucson, AZ	1-Sep-17	Developer of gene modification and cell delivery technology to shield and strengthen the immune system to create enduring and life-long protection for individuals living with a broad range of debilitating and currently incurable diseases.	416.00
1mg	Dawailelo	Varanasi, India	1-Sep-17	Developer of an online healthcare platform that provides medicine and related medical supplies based on the prescribed reports of healthcare professionals.	Undisclosed
QPharma	MedStart Connect	San Diego, CA	1-Sep-17	Provider of patient outreach adherence calls and prescription home delivery to support continuing medication adherence.	Undisclosed
Nexeon MedSystems	Nexeon Medsystems Belgium	Isnes, Belgium	1-Sep-17	Developer of technologies and applications that interface with the nervous system to treat a variety of diseases, including atrial fibrillation, overactive bladder, and brain cancers.	Undisclosed
Jubilant Draximage	Triad Isotopes	Orlando, FL	1-Sep-17	Developer and marketer of nuclear pharmaceuticals used for both diagnostic and imaging procedures.	Undisclosed
Diaxonhit	GenBio	San Diego, CA	5-Sep-17	Developer, manufacturer, and marketer of immunoassay products.	2.00
Bio-Techne	Trevigen	Gaithersburg, MD	5-Sep-17	Provider of researching tools and equipment intended for exploring DNA damage and repair in relation to cancer research.	Undisclosed
PRA Health Sciences	Symphony Health	Conshohocken, PA	6-Sep-17	Provider of high-value data, analytics, and technology services intended to deliver strategic market data insights and help professionals understand the full market lifecycle, from predictive market analysis to patient influence, physician prescribing, pharmacy fulfillment, payer reimbursement, and sales compensation.	530.00
Bristol-Myers Squibb	IFM Therapeutics	Boston, MA	7-Sep-17	Developer of small molecule drugs targeting the innate immune system for the treatment of cancer, autoimmunity, and inflammatory disorders.	2320.00
Citadel Group	Charm Health	Paddington, Australia	15-Sep-17	Provider of specialist oncology electronic medical record systems.	6.49
Christie & Co	Houghton Pharmacy	Houghton-Le-Spring, United Kingdom	15-Sep-17	Provider of medication and pharmaceutical products.	Undisclosed

Mergers and Acquisitions

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Opexa Therapeutics	Acer Therapeutics	Cambridge, MA	19-Sep-17	Developer of pharmaceutical therapeutics designed to treat serious rare diseases, including vascular ehlers-danlos syndrome and urea cycle disorders.	Undisclosed
Acer Therapeutics	Opexa Therapeutics	The Woodlands, TX	19-Sep-17	Provider and developer of patient-specific cellular therapies for the treatment of autoimmune diseases.	Undisclosed
Mallinckrodt	InfaCare Pharmaceuticals	Treose, PA	25-Sep-17	Manufacturer of a pharmaceutical drug for the treatment of neonatal jaundice.	425.00
MoneyTrac Technology	PotSaver	San Diego, CA	27-Sep-17	Producer of cannabis products for local dispensaries and shops.	Undisclosed
Ravencrest Resources	Alberta Green Biotech	Edmonton, Canada	28-Sep-17	Producer of medical marijuana.	0.94
Saol International	Venus BioTherapeutics	Seattle, WA	28-Sep-17	Provider of biotechnology products and services.	74.50